ALMS — Alumis Inc.

Is ALMS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Alumis Inc. (ALMS) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $5.14. The rating moved from Oversold to Strong Oversold on November 14, 2026.

See all oversold Healthcare stocks →

AI analysis

Alumis Inc. lacks readily available public financial detail, creating material uncertainty around liquidity and near‑term execution. Market conditions are currently supportive of growth and earnings‑driven moves, and sector themes (at‑home care, specialty distribution, device approvals) could provide potential upside if the company captures partnerships or regulatory progress. Key risks include disclosure gaps, dilution, regulatory/reimbursement hurdles and competitive pressure; absent clearer financials or confirmed catalysts, a neutral stance with close monitoring of filings, press releases and cash‑related disclosures is appropriate.

Key factors

  • Limited publicly available company-specific financial and EDGAR disclosures, producing uncertainty around cash runway and recent operating performance
  • Small‑cap liquidity and volatility typical for companies of this size, which can amplify share moves around news or earnings
  • Sector-level tailwinds in specialty distribution, at‑home care modalities, and device approvals that could create commercial opportunities if Alumis has relevant assets or partnerships
  • Current market environment mildly risk‑on with investor focus on earnings rather than macro shocks, which can support short-term price stability
  • Potential near‑term catalysts from corporate announcements, partner deals or clinical/regulatory updates (absent public filings these are speculative)

Risks

  • Insufficient disclosure: lack of recent filings or financial detail increases execution and valuation uncertainty
  • Regulatory and reimbursement risk that could delay or limit commercialization of any product assets
  • Dilution risk from potential equity or convertible financings common in small/biotech companies
  • Competitive pressure from larger incumbents and well‑funded entrants in adjacent healthcare/device markets
  • Low social sentiment and analyst coverage increases probability of sharp moves on limited news and reduces liquidity
  • Macro/market risk: a reversal in risk appetite or wider healthcare de‑risking could materially depress share price

See today's live rating, score and targets

Members see the live hourly rating for ALMS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.